Experimental drug for rare skin disease fails to reach goal
NCT ID NCT05979831
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was terminated early, so we don't have clear answers on its effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DS-2325a
- What this could lead to
- If it had worked, this could have pointed toward a treatment to control the severe skin symptoms of Netherton syndrome.
- What could go wrong
- The trial was terminated early with only 9 participants, so results are very limited. It is unclear if DS-2325a is safe or effective, and it may never be developed further.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Saint Louis Hospital
Paris, 75012, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New lotion shows promise for rare skin disorder
- Scientists hunt for clues to ichthyosis in skin and blood
- Could arthritis drug humira ease rare skin disease?
- Microbiome study seeks clues in rare skin condition
- New cream shows promise for rare skin condition
- Rare skin disease mystery unraveled: new study maps netherton Syndrome's inner workings